Pulse Biosciences, Inc

17.11-0.24 (-1.38%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · PLSE · USD

Upcoming Earnings

Report date
Nov 5, 2025 (in 6 days)

Key Stats

Market Cap
1.16B
P/E (TTM)
-
Basic EPS (TTM)
-1.08
Dividend Yield
0%

Recent Filings

About

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

CEO
Mr. Paul Arthur LaViolette
IPO
5/18/2016
Employees
75
Sector
Healthcare
Industry
Medical Instruments & Supplies